Figure 2.
(A) Mean plasma concentration‐time profiles following single doses of mevidalen from part A of the SAD study. (B) Mean plasma and CSF concentration‐time profiles following single doses of mevidalen from part B of the SAD study.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.